Matches in DBpedia 2014 for { ?s ?p 25B-NBOMe (NBOMe-2C-B, BOM 2-CB, Cimbi-36, New Nexus, Nova) is a derivative of the phenethylamine hallucinogen 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor. Anecdotal reports from users[citation needed] suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250-500 µg,[citation needed] making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly. Duration of effects lasts about 12–16 hours.[citation needed]The carbon-11 labeled version of this compound ([11C]Cimbi-36) was synthesized and validated as a radioactive tracer for positron emission tomography (PET) in Copenhagen. As a 5-HT2A receptor agonist PET radioligand, [11C]Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, [11C]Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels in vivo. [11C]Cimbi-36 is now undergoing clinical trials as a PET-ligand in humans.. }
Showing items 1 to 1 of
1
with 100 items per page.
- 25B-NBOMe abstract "25B-NBOMe (NBOMe-2C-B, BOM 2-CB, Cimbi-36, New Nexus, Nova) is a derivative of the phenethylamine hallucinogen 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor. Anecdotal reports from users[citation needed] suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 250-500 µg,[citation needed] making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly. Duration of effects lasts about 12–16 hours.[citation needed]The carbon-11 labeled version of this compound ([11C]Cimbi-36) was synthesized and validated as a radioactive tracer for positron emission tomography (PET) in Copenhagen. As a 5-HT2A receptor agonist PET radioligand, [11C]Cimbi-36 was hypothesized to provide a more functional marker of these receptors. Also, [11C]Cimbi-36 is investigated as a potential marker of serotonin release and thus could serve as an indicator of serotonin levels in vivo. [11C]Cimbi-36 is now undergoing clinical trials as a PET-ligand in humans.".